Insurance Paperwork Hits Nearly Half of Cancer Survivors, Study Finds

Nearly half of cancer survivors in a new United States study report battling insurance-related administrative burdens years after their diagnosis, and the type of treatment they received, not the type of insurance they held, appears to be the strongest predictor of that bureaucratic friction. The findings, published in the Journal of Cancer Survivorship, offer one of the most detailed portraits yet of how prior authorizations, claim denials, surprise bills, stepped-care requirements and out-of-network charges accumulate in the lives of people who have already endured cancer treatment.

The research team, led by investigators at the Fred Hutchinson Cancer Center in Seattle, surveyed 459 cancer survivors who were, on average, eleven years past their initial diagnosis. That long follow-up window is significant. Most studies of financial toxicity in oncology focus on patients in active treatment, when bills are arriving in a torrent. This study instead asked whether the administrative aftermath of cancer persists long into survivorship, and the answer appears to be yes: 46 percent of participants reported experiencing at least one insurance-related administrative burden.

The researchers examined five distinct categories of administrative burden. Prior authorization, the requirement that an insurer approve a treatment before it is delivered, was reported by 33 percent of survivors who had received immunotherapy. Surprise bills, unexpected charges for services patients believed were covered, affected 46 percent of immunotherapy recipients and 33 percent of those who had undergone surgery. Stepped care, in which insurers require patients to try less expensive therapies before approving others, was reported by 26 percent of immunotherapy patients and 17 percent of chemotherapy recipients. Claim denials were reported by 22 percent of chemotherapy patients and 24 percent of those who had received radiation therapy, while out-of-network charges affected 16 percent of surgical patients. All of these associations were statistically significant.

Perhaps the most striking result is what did not predict these burdens. The type of health insurance a survivor had at the time of diagnosis, whether employer-sponsored, public or otherwise, showed no statistically significant association with the likelihood of experiencing administrative burdens. In other words, the paperwork gauntlet appears to cut across the American insurance landscape, afflicting the privately insured and publicly insured alike. This challenges a common assumption that problems with prior authorization and denials are concentrated in particular insurance products or payer categories.

The study also measured financial toxicity across four dimensions, a framework that treats the financial fallout of cancer as a genuine clinical side effect rather than a mere accounting problem. Financial toxicity encompasses out-of-pocket costs, but also the psychological distress of debt, the behavioral changes families make to cope with bills, and the anxiety and depression that money worries generate. Previous research has linked high financial toxicity to worse quality of life, greater psychological distress and even earlier mortality among patients with cancer, making it a target for intervention in its own right.

Here the treatment picture diverged from the burden picture. Survivors who had undergone surgery, chemotherapy or immunotherapy reported significantly more financial coping behaviors than those who had not received those treatments, meaning they had taken concrete steps to manage the financial damage, such as borrowing, cutting expenses or working extra hours. Insurance type mattered in a narrower way: compared with survivors covered by employer- or school-sponsored insurance, those who had purchased their own insurance reported more financial depression, anxiety and coping. Most other insurance types showed no such association.

Why would immunotherapy and chemotherapy carry such heavy administrative loads? The authors point to the mechanics of how these drugs are approved and paid for. Immunotherapies, which have transformed the treatment of melanoma and many other cancers since the first checkpoint inhibitor was approved in 2011, are among the most expensive injectable drugs in medicine, and their costs have continued to climb after launch. Expensive, specialty drugs are precisely the category that insurers police most aggressively with prior authorization requirements, step therapy protocols and utilization review. Chemotherapy, similarly, sits at the intersection of high cost and complex billing, where coding disputes and coverage questions can easily harden into formal denials.

Surgery and radiation therapy carry different risks. Surgical patients in the study were more likely to report surprise bills and out-of-network charges, a pattern consistent with the well-documented problem of ancillary providers, such as anesthesiologists and pathologists, participating in an operation while remaining outside the patient’s insurance network. Radiation oncology has also been identified in prior literature as a field where prior authorization imposes substantial delays and administrative work. The new findings suggest that no major cancer treatment modality is free of administrative risk, even if the specific burden differs by modality.

The implications for survivors and clinicians are considerable. The study’s authors note that immunotherapy and chemotherapy may confer the highest risk of administrative burdens, but that surgery and radiation can also expose patients to them. Because insurance type at diagnosis did not predict burdens, clinicians cannot easily identify which patients will need help simply by looking at their coverage. Instead, the treatment received may serve as a better signal, allowing financial navigators and care teams to target screening and assistance toward patients whose treatment plans carry elevated administrative risk. Financial navigation programs, which have shown promising primary outcomes in randomized trials for newly diagnosed patients, may need to extend their reach deeper into survivorship.

The research also contributes to a growing social science literature on administrative burden, the learning, compliance and psychological costs that citizens pay when interacting with state and bureaucratic systems. Applied to health insurance, this framework reframes prior authorizations and denials not as isolated annoyances but as a cumulative tax on patients’ time, attention and emotional reserves, levied on people who are often still recovering from life-threatening illness. With nearly half of long-term survivors in this sample reporting at least one such burden, and with burdens linked to more intensive financial coping, the study suggests that the administrative machinery of American health insurance operates as a persistent, treatment-linked stressor in cancer care, one that persists long after the last infusion or radiation session and that no category of coverage reliably shields patients from.

Subject of Research: Administrative burdens and financial toxicity among cancer survivors by insurance type and treatment received

Article Title: Examination of insurance type and cancer treatments with administrative burdens and financial toxicity in a sample of cancer survivors

Article References: Lu, A. Z., Yi, J. C., Henrikson, N. B., Panattoni, L. E., Lowry, D., Harkey, K., & Jones, S. M. W. (2026). Examination of insurance type and cancer treatments with administrative burdens and financial toxicity in a sample of cancer survivors. Journal of Cancer Survivorship. https://doi.org/10.1007/s11764-026-02116-z

Image Credits: AI Generated

DOI: 10.1007/s11764-026-02116-z

Keywords: cancer survivors, financial toxicity, administrative burden, prior authorization, health insurance, immunotherapy, chemotherapy, surprise bills, claim denials, radiation therapy, financial coping, Journal of Cancer Survivorship